BenzingaAugust 10, 2026 at 12:24 PM NY25 days ago
Alumis Reports Topline Results From Ongoing ONWARD3 Long-Term Extension Study Showing 54% Of Patients Reached Complete Skin Clearance After 48 Weeks Of Continuous Envudeucitinib Treatment
– Favorable long-term safety and tolerability profile remained consistent with previously reported data –– On track to submit a New Drug Application to FDA in 4Q 2026 –SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Which dow jones stocks are moving on Friday?
ChartMill3 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill3 hours ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo3 hours ago
Sector Update: Financial
Yahoo5 hours ago
Should You Buy, Sell or Hold PVH Stock Post Q2 Earnings?
Yahoo5 hours ago